AGENUS INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
AGENUS INC (AGEN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $2.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-16
- AGENUS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $2.29M, a 24.85% decline from fiscal 2024.
- AGENUS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $3.05M, a 1.55% decline from fiscal 2023.
- AGENUS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $3.10M, a 3.40% increase from fiscal 2022.
- AGENUS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $3.00M, a 31.00% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.29M 10-K · filed 2026-03-16 | |
| 2024-12-31 | $3.05M 10-K · filed 2026-03-16 | |
| 2023-12-31 | $3.10M 10-K · filed 2026-03-16 | $4.70M 10-K · filed 2024-03-14 |
| 2022-12-31 | $3.00M 10-K · filed 2025-03-17 | |
| 2021-12-31 | $2.29M 10-K · filed 2024-03-14 | |
| 2020-12-31 | $1.88M 10-K · filed 2023-03-16 | |
| 2019-12-31 | $1.37M 10-K · filed 2022-03-01 | |
| 2018-12-31 | $4.22M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |